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Abstract
 
To gain insight into the biological role of mast cell chymase we have generated a mouse strain
with a targeted deletion in the gene for mast cell protease 4 (mMCP-4), the mouse chymase
that has the closest relationship to the human chymase in terms of tissue localization and func-
tional properties. The inactivation of mMCP-4 did not affect the storage of other mast cell
proteases and did not affect the number of mast cells or the mast cell morphology. However,
mMCP-4 inactivation resulted in complete loss of chymotryptic activity in the peritoneum and
in ear tissue, indicating that mMCP-4 is the main source of stored chymotrypsin-like protease
activity at these sites. The mMCP-4 null cells showed markedly impaired ability to perform in-
activating cleavages of thrombin, indicating a role for mMCP-4 in regulating the extravascular
coagulation system. Further, a role for mMCP-4 in connective tissue remodeling was suggested
by the inability of mMCP-4 null peritoneal cells to process endogenous fibronectin.
Key words: chymase • mast cell • ﬁbronectin • thrombin • mouse mast cell protease 4
 
Introduction
 
Mast cells (MCs)
 
*
 
 are mainly known for their harmful effects
during allergic inflammation (1). However, recent investiga-
tions using MC-deficient mice have shown that MCs are
essential for the manifestation of various other types of dis-
ease, e.g., experimental allergic encephalomyelitis (rodent
analogue to multiple sclerosis; reference 2), antibody-
induced rheumatoid arthritis (3), tumor angiogenesis (4),
and experimental bullous pemphigoid (5). When MCs are
activated, e.g., by cross-linking of IgE bound to their high
affinity receptor Fc
 
 
 
RI by specific antigen, they respond by
degranulation with the concomitant release of a panel of
preformed inflammatory mediators such as histamine, cyto-
kines, proteoglycans, and various neutral proteases. In addi-
tion, MC activation leads to de novo synthesis and release
of several lipid-derived mediators, e.g., PGD
 
2
 
, LTC
 
4
 
, and
platelet activating factor (for reviews, see references 6–8).
The neutral proteases fall into three classes: tryptases,
chymases, and carboxypeptidase A (CPA; for reviews, see
references 9–11). The chymases are chymotrypsin-like
serine proteases, and are further divided, based on struc-
tural comparisons, into 
 
 
 
-chymases and 
 
 
 
-chymases. In
humans only one chymase gene, belonging to the 
 
 
 
-fam-
ily, has been identified. In contrast, rodents have been
shown to express a number of 
 
 
 
-chymase genes, desig-
nated mouse MC protease 1 (mMCP-1), mMCP-2, and
mMCP-4 as well as one 
 
 
 
-chymase, mMCP-5. The dif-
ferent chymases differ significantly as regards tissue distri-
bution. Connective tissue type MCs (CTMCs; located in
various tissues such as skin, tongue, peritoneum) show
predominant expression of mMCP-4 and –5 whereas the
mucosal subtype of MCs (MMCs; located in the intestinal
tract) instead express mMCP-1 and –2. In addition to
mMCP-4 and –5, CTMCs express the tryptases mMCP-6
and –7 as well as CPA, all of which are lacking in MMCs.
The CTMC chymases are stored in tight complexes with
heparin proteoglycan in the secretory granules. In contrast,
the MMC chymases are of lower affinity for the negatively
charged glycosaminoglycans present in the secretory gran-
ule and may, accordingly, be constitutively secreted by the
MCs (12).
 
Address correspondence to Magnus Åbrink, Swedish University of Agri-
cultural Sciences, Department of Molecular Biosciences, The Biomedical
Center, Box 575, 751 23 Uppsala, Sweden. Phone: 46-18-4714192; Fax:
46-18-550762; email: magnus.abrink@bmc.uu.se 
 
*
 
Abbreviations used in this paper:
 
 CPA, carboxypeptidase A; CTMC,
connective tissue type mast cell; MC, mast cell; MMC, mucosal mast
cell; mMCP, mouse mast cell protease; NDST, N-deacetylase/N-sul-
fotransferase.T
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The fact that the only human chymase gene known be-
longs to the 
 
 
 
-family suggests that mMCP-5, the only
 
 
 
-chymase in mouse, may be the murine counterpart of
human chymase. However, recent data have shown that
mMCP-5, due to an amino acid difference in position 216
(Val instead of the Gly that is present in human chymase),
does not have chymotrypsin-like activity but in fact has
elastase-like specificity (13). Thus, it is likely that the func-
tional counterpart to human chymase may be found in the
rodent 
 
 
 
-chymase family. Of the known mouse 
 
 
 
-chy-
mases, mMCP-4 has the most similar tissue distribution as
human chymase, e.g., skin, and has also similar heparin-
binding (14, 15) and angiotensin I-converting (16) proper-
ties. It may therefore be suggested that mMCP-4 is the
functional homologue to human chymase. While the other
CTMC-specific chymase, mMCP-5, as well as CPA and
the tryptases mMCP-6, and –7 are expressed early during
MC differentiation induced by IL-3, mMCP-4 is only ex-
pressed after inducing terminal MC differentiation with
stem cell factor (17).
Previous investigations have indicated a role for chymase
in various inflammatory conditions. Injection of human
chymase into the skin of guinea pigs was shown to cause
marked neutrophil influx and was also shown to cause in-
creased vascular permeability (18, 19). More recently it has
been shown that specific chymase inhibitors may ameliorate
a variety of pathological conditions, including fibrosis in
NC/Nga mice (20), eosinophil accumulation in mice in-
fected with 
 
Nippostrongylus brasiliensis
 
 (21), allergen-induced
skin reactions (22), and angiogenesis in hamster sponge
granulomas (23). It is important to stress that although the
reports described above provide evidence for an involve-
ment of chymases in various pathological conditions, the
exact mode of action for chymase has not been determined,
i.e., the in vivo substrates for chymases have not been iden-
tified. Further, limited knowledge is available as regards the
individual contribution of the various MC chymases. To
gain further insight into the biological role of MC chymase
we have here inactivated the gene for mMCP-4.
 
Materials and Methods
 
Reagents.
 
The chromogenic peptide substrates S-2586,
S-2238 and S-2288 were from Chromogenix. The CPA substrate
M-2245 (N-(4-Methoxyphenylazoformyl)-Phe-OH was from
Bachem). Bovine 
 
 
 
-thrombin was a gift from Ingemar Björk
(Swedish University of Agricultural Sciences, Dept. of Veterinary
Medical Chemistry, Uppsala, Sweden). The calcium ionophore
A23187 was purchased from Calbiochem. Purified anti–mouse
IgE (R35–72) was from BD Biosciences, donkey anti–rabbit Ig
conjugated to horseradish peroxidase was purchased from Amer-
sham Biosciences, and goat anti–rat Ig conjugated to horseradish
peroxidase was purchased from Sigma-Aldrich. Antisera toward
mMCP-4, -5, -6, and CPA were as described (24). The antisera to
mMCP-4 and –5 were gifts from Lars Hellman (Uppsala Univer-
sity, Uppsala, Sweden). Antisera against mMCP-4, mMCP-6,
CPA, and fibronectin were raised in rabbits whereas the antiserum
toward mMCP-5 was of rat origin. The anti-fibronectin antise-
rum was a kind gift from Staffan Johansson (Uppsala University).
 
Knockout Techniques.
 
A 
 
 
 
16 kb fragment of the mMCP-4
gene was cloned from a 129SVJ mouse genomic lambda FIX II
library (Stratagene) using a full-length mMCP-4 cDNA as probe
(a kind gift from Lars Hellman [Uppsala University, Sweden]).
The 16 kb genomic fragment was released from the library vector
with NotI enzyme and subcloned into the pZero vector (Invitro-
gen). The subcloning allowed further characterization of the
structure of the mMCP-4 gene and identification of suitable re-
striction sites for construction of the target vector to be used for
homologous recombination in ES cells. A BamH1 site was identi-
fied between exons 1 and 2, and this site together with the NotI
site of the pZero/lamda vector was used for cloning of a 
 
 
 
4.5 kb
downstream arm of the mMCP-4 gene into the target vector
(Fig. 1 B). A suitable 
 
 
 
3 kb fragment with EcoRI and BglII sites
was found upstream of the mMCP-4 gene, covering the promo-
tor region (Fig. 1 B). The blunted EcoRI and BglII sites were
used for cloning of the upstream arm into a blunted XhoI site of
the target vector containing the neo cassette (indicated by solid
lines connecting the upper and lower parts of Fig. 1 B). This
strategy thus deletes exon 1 of the mMCP-4 gene. The targeting
vector was electroporated into ES cells using 1.5 
 
 
 
g of DNA/10
 
6
 
ES cells. The ES cell work was performed using a standard proto-
col but without negative selection, i.e., omitting the selection
against thymidine kinase expression. Cell cultures derived from
the different ES cell clones obtained were divided into two por-
tions. One of the portions was frozen (
 
 
 
80
 
 
 
C) whereas the re-
maining cells were cultured further and used for preparation of
genomic DNA.
A PCR based strategy was designed and used for the screening
of possible positive clones: one oligonucleotide primer, specific
for the neomycin cassette (primer II; see Fig. 1 B), was used to-
gether with a primer located outside the construct, upstream from
the mMCP-4 gene (primer I; see Fig. 1 B). In clones where ho-
mologous recombination had occurred, these primers will give
rise to a 5 kb fragment upon PCR amplification. Amplification
was performed with shuttle PCR using TaKaRa enzyme with
annealing and melting temperatures of 68
 
 
 
C and 98
 
 
 
C, respec-
tively. Approximately 400 ES cell clones were screened and out
of these we identified 6 ES cell clones where homologous recom-
bination had occurred, i.e., a 5 kb PCR product was obtained us-
ing primers I and II. To verify that the homologous recombina-
tion was correct a second PCR was performed. We designed one
primer (primer VI; see Fig. 1 B) for specific targeting downstream
of the construct that, in combination with primer V (see Fig. 1 B),
should yield a 7 kb PCR product. All six clones gave the ex-
pected size in the second PCR. Clone number 338 was chosen
for injection into blastocysts. Injected blastocysts were implanted
into pseudo-pregnant C57/CBA F1 mice, and a total of four chi-
meras were generated. One chimera gave germline transmission
of the targeting construct (the other three chimeras were not fur-
ther tested). Genotyping of F1 offspring (using tail DNA) by the
described PCR approach (see above, using primer I and II) iden-
tified the 5 kb PCR product in the expected 50% ratio. Het-
erozygous animals were backcrossed to the C57BL/6J strain. F1
and F2 heterozygote animals were then crossed to obtain animals
homozygous for the mutation. The mMCP-4 null genotype was
found in the expected 25% ratio among the offspring. The
mMCP-4
 
 
 
/
 
 
 
 animals do not show any difference from their
wild-type and heterozygote littermates when studied for pheno-
typic or behavioral signs using a simplified version of the
SHIRPA protocol (25). Homozygous null animals were mated
and were found to be fertile. For the purpose of this study, we
used null mice obtained from crossings of heterozygote animals ofT
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either F1 or F2 generations. In all cases, 
 
 
 
/
 
 
 
 and 
 
 
 
/
 
 
 
 littermates
were used as controls.
 
Cell Culture.
 
Peritoneal cells from mMCP-4
 
 
 
/
 
 
 
 mice and
corresponding mMCP-4
 
 
 
/
 
 
 
 or 
 
 
 
/
 
 
 
 littermates (8–12 wk old)
were collected by peritoneal washing with 10 ml of cold PBS, pH
7.4. Cells were centrifuged (300 
 
g
 
, 4
 
 
 
C, 10 min) and cultured in
serum-free medium, HybridoMed DIF (Biochrom KG). The se-
rum-free medium was supplemented with 50 
 
 
 
g/ml of gentamy-
cin (GIBCO BRL). The cells were distributed in 24-well plates
(Nunc; 
 
 
 
0.5 
 
 
 
 10
 
6
 
 cells in 0.4 ml/well). Cells were incubated at
37
 
 
 
C in a humidified atmosphere of 5% CO
 
2
 
. For activation of
MCs, either the calcium ionophore A23187 (final concentration
2 
 
 
 
M), or anti–mouse IgE (2 
 
 
 
g) were added. To study the abil-
ity of the peritoneal cells to inactivate thrombin, 1 
 
 
 
g of throm-
bin (in 10 
 
 
 
l PBS) was added to the cell cultures. Samples from
the conditioned media (50 
 
 
 
l) were taken at various time points
and were frozen at –20
 
 
 
C. For analysis of residual thrombin activ-
ities, 20 
 
 
 
l of the samples were added to individual wells of 96-
well microtiter plates, followed by the addition of 200 
 
 
 
l PBS
and 20 
 
 
 
l of a 1.8 mM (in H
 
2
 
O) solution of the chromogenic
thrombin substrate S-2238. The absorbance at 405 nm was mon-
itored with a Titertek Multiscan spectrophotometer (Flow Labo-
ratories) and initial reaction velocities were determined with the
DeltaSoft3 software.
 
Analysis of Protease Activities in Tissues.
 
Ear extracts were ob-
tained by the addition of 1 ml of PBS/2 M NaCl per ear, fol-
lowed by homogenization using a PT1200 Polytron device (Ki-
nematica AG). After homogenization, Triton X-100 was added
to give a final concentration of 0.5%. Extracts were centrifuged
(10,000 
 
g
 
), the supernatants were recovered and samples from the
supernatants were used for activity measurements. Peritoneal cells
(2 
 
 
 
 10
 
6
 
 cells) were solubilized in 200 
 
 
 
l lysis buffer (PBS/2 M
NaCl, 0.5% Triton X-100). 10 
 
 
 
l of the peritoneal cell or ear ex-
tracts were mixed with 90 
 
 
 
l H
 
2
 
O, followed by the addition of
20 
 
 
 
l of 1.8 mM solutions (in H
 
2
 
O) of chromogenic substrates
for either chymotrypsin-like proteases (S-2586), trypsin-like pro-
teases (S-2288), or CPA (M-2245). Changes in absorbance at 405
nM were measured as above.
 
Western Blot Analysis.
 
Samples of ear tissue extracts, solubi-
lized peritoneal cells or cell culture media were mixed with 3
 
 
 
SDS-PAGE sample buffer containing 5% 
 
 
 
-mercaptoethanol.
Samples (40 
 
 
 
l) of these mixtures were subjected to SDS-PAGE
on 12% gels. Proteins were subsequently blotted onto nitrocellu-
lose membranes, followed by blocking with 5% milk powder in
PBS (overnight, 20
 
 
 
C). Next, the membranes were incubated
with antisera (1:250) in TBS/5% milk powder/0.1% Tween 20, at
20
 
 
 
C for 1 h. After washing the membranes extensively with
TBS/0.1% Tween 20, the membranes were incubated with sec-
ondary antibody (anti–rat or anti–rabbit, respectively) conjugated
to horseradish peroxidase (Amersham Biosciences; 1:3,000 dilution
in TBS/0.1% Tween 20). After 45 min of incubation at 20
 
 
 
C, the
membranes were washed extensively with TBS/0.1% Tween 20,
followed by washing with TBS without detergent. The mem-
branes were developed with the ECL system (Amersham Bio-
sciences) according to the protocol provided by the manufacturer.
 
Results
 
Genomic Organization of MC Chymase Genes.
 
A geno-
mic contig spanning the entire mouse chymase locus on
chromosome 14 was extracted from the Sanger Institute’s
database, Ensembl Mouse Blast view (in April 2003). The
organization of the chymase genes over a total of 160 kb of
 
DNA starts with the mMCP-5 gene which is followed
downstream by the mMCP-1 (at 75 kb; in opposite orien-
tation), mMCP-9 (at 85 kb), mMCP-2 (at 105 kb; in op-
posite orientation), mMCP-4 (at 125 kb), and finally, at
155 kb, the mMCP-8 gene (Fig. 1 A). In addition we also
identified the possible location of the mMCP-L (at 13 kb)
and mMCP-10 (at 30 kb; in opposite orientation) genes.
Interestingly, the transcriptional orientations of the CTMC
chymases (mMCP-4 and mMCP-5) are opposite to those
of the MMC protease(s) (mMCP-1 and mMCP-2). Possi-
bly, the tissue-specific transcription of the CTMC and
MMC chymase genes, respectively, may be related to their
genomic orientation. The mMCP-9 gene, considered to be
expressed in uterine MCs only (26), and the mMCP-8
gene, which has been suggested to be a basophilic cell
marker (27), have the same transcriptional orientations as
the CTMC chymases.
Previous work has identified highly conserved promotor
regions in the mMCP-1, -2, -4, and –L genes (28). In addi-
tion, Kitamura and coworkers have shown in several stud-
ies that most chymase genes are regulated by the transcrip-
tion factor MITF through specific E-boxes located 300 to
1,200 bases upstream of respective gene (29, and references
therein). A comparison of the promotor region of mMCP-9
(26), bases 
 
 
 
1 to –1,200, against the chymase locus ex-
tracted from the Sanger database reveals a number of ho-
mologous DNA segments throughout the entire locus (Fig.
1 A). The promotor regions in the mMCP-1, -2, -4, -L,
and –10 genes all share homology with the promotor re-
gion of mMCP-9 (“x” in Fig. 1 A). Note also that “x” pro-
motor regions are present at positions without any connec-
tion to a known chymase gene. In contrast, the promotor
region of mMCP-5 (“y” in Fig. 1 A), bases 
 
 
 
5 to –905, re-
veals only a partial homology with one segment of the chy-
mase locus (located at 40 kb; see Fig. 1 A). The promotor
region of mMCP-8 (“z” in Fig. 1 A), bases 
 
 
 
1 to –825,
does not show any homology with other parts of the chy-
mase locus, in agreement with a previous study (30).
 
Construction of Targeting Vector, Electroporation, Production
of Knockout Mice.
 
After successful screening of the 129SVJ
genomic library and subcloning of the mMCP-4 gene frag-
ment we cloned two arms (Fig. 1 B) into the pNeo plasmid
and used the target construct for electroporation into ES
cells (GSI-I). 400 clones were screened for the mutation us-
ing a PCR-based strategy. A total of six positive clones were
identified and one of these (clone 338) was used for blasto-
cyst injection. Implantation of injected blastocysts into
pseudo-pregnant C57/CBA F1 females resulted in chimeric
animals and subsequent breeding of these revealed germ line
transmission of the targeting construct. The agouti F1 ani-
mals were genotyped by PCR using the primer pair I
 
 
 
II
(see Fig. 1 B), which should give a 5 kb product. As ex-
pected, 
 
 
 
50% of the animals were heterozygous for the
mMCP-4 mutation. Heterozygous F1 animals were then
crossed to obtain homozygous mMCP-4 null animals. The
offspring from these crossings arrived at the expected Men-
delian frequencies: 25% wt, 50% heterozygous, and 25% ho-
mozygous for the mMCP-4 mutation. To identify animalsT
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that were homozygous for the mMCP-4 mutation, the off-
spring was genotyped by PCR using the primer pair I
 
 
 
IV
(see Fig. 1 B), that should yield a 7 kb product. Indeed, het-
erozygous animals gave two products of expected sizes, 5.5
kb for the wt- and 7 kb for the targeted allele. However, the
7 kb PCR product was barely detectable on gel (see Fig. 1 C)
but was easily detected by southern hybridization using the
neo-specific primers (II or V, Fig. 1 B) as probes (unpub-
lished data). The homozygous null animals were identified
by the presence of the 7 kb PCR product only (Fig. 1 C).
 
Effect of mMCP-4 Inactivation on MC Phenotype.
 
Two
different MC-rich tissues, the peritoneum and ears, were
used to study the consequence of the mMCP-4 inactiva-
tion on MC phenotype. Immunoblot analysis using a spe-
cific antibody to mMCP-4 (24) confirmed that the mutant
mice lacked immunoreactive mMCP-4 protein, whereas
mMCP-4 antigen was readily detected in wt cells both
from peritoneum and ear tissue (Fig. 2). Previous investiga-
tions have shown that the lack of one MC mediator may
affect the storage of other MC mediators (31, 32). There-
fore, experiments were performed to assess whether the
lack of mMCP-4 influenced the presence of the other
CTMC proteases, mMCP-5, -6, and CPA. However, im-
munoblot analysis revealed that the mMCP-4 inactivation
did not lead to any marked effect on the concentration of
any of these proteases in peritoneal cells (Fig. 2).
 
The inactivation of the mMCP-4 gene did not affect the
number of MCs being present in the peritoneum, with
 
 
 
2–3% of the cells in both wt and mMCP-4
 
 
 
/
 
 
 
 animals
being identified as MCs by staining with May-Grünwald/
Giemsa. Moreover, the mMCP-4 inactivation did not lead
to any noticeable effects on MC size or apparent morphol-
ogy (Fig. 3). We also investigated if the mMCP-4
 
 
 
/
 
 
 
 MCs
responded normally to MC-degranulating agents. Results
displayed in Fig. 3 show that treatment of both wt and
mMCP-4
 
 
 
/
 
 
 
 MCs with either the calcium ionophore
A23187 or anti-IgE antibody resulted in MC degranulation.
 
Contribution of mMCP-4 to Total Amount of Stored Chy-
motrypsin-like Activities in Tissues.
 
Studies were performed
to study the contribution of mMCP-4 to the total amount
of stored chymotrypsin-like activities in the peritoneal cell
population and in ear tissue. Further, the possibility that the
lack of mMCP-4 could influence the levels of other pro-
tease activities was investigated. Results displayed in Tables
I and II show that chymotrypsin-like activities were clearly
detected in both peritoneal cells and in ear tissue extracts
from mMCP-4
 
 
 
/
 
 
 
 animals. However, the targeting of
mMCP-4 completely abolished the chymotrypsin-like ac-
tivities in these tissues, demonstrating that mMCP-4 is the
major source for chymotrypsin-like activity in peritoneal
cells and in ear tissue. The inactivation of mMCP-4 did not
lead to any marked effects on the levels of trypsin-like or
Figure 1. (A) Genomic orga-
nization of the mouse MC chy-
mase locus. The positions of the
different chymase genes and their
transcriptional orientations are
indicated by arrows. mMCP-5
and mMCP-8, which are clearly
different from the other chy-
mases in terms of structure or tis-
sue specificity (see Results), are
positioned at the flanks of the lo-
cus. The more closely related
chymases mMCP-1, -2, -4, and
–9 are clustered in the middle of
the locus. (B) Construct used for
targeting of the mMCP-4 gene.
Detailed organization of a 16 kb
genomic fragment covering the
mMCP-4 gene and 12 kb of up-
stream regions. EcoRI, BglII,
and BamHI indicate restriction
sites found. Depicted is also the
final targeting construct used
for homologous recombination.
Neo corresponds to the neomy-
cin resistant cassette used in the
target vector, with promotor
(PGK) and transcriptional orien-
tation (arrow) indicated. Roman
numerals indicate the positions
of primers used in genomic PCR
(primer I is upstream outside
construct, II is inside Neo, III is in exon 1, IV is in exon 2, V is reverse complementary to II, VI is downstream outside construct). (C) PCR screening of
targeted mice. Genomic DNA was prepared from WT ( / ), heterozygous ( / ) or homozygous ( / ) littermates and was subjected to PCR analysis
to trace the mMCP-4 mutation. PCR products were separated on 1% agarose gels. The top panel shows a standard result using primers I II, yielding the
5 kb product characteristic of the mutant mMCP-4 gene. The bottom panel shows the result obtained using primers I IV, where the insertion of the
mutant mMCP-4 gene results in a 7 kb PCR product.T
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CPA activities in peritoneal cells or ear tissue, indicating
that mMCP-4 does not influence the activity of the other
CTMC proteases.
 
mMCP-4 Inactivation Results in Impaired Ability to Regulate
Thrombin.
 
In an earlier study we showed that peritoneal
cells have potent thrombin-inactivating activity, but
that the thrombin-inactivating activity was severely com-
promised in cell cultures derived from mice lacking
N-deacetylase/N-sulfotransferase 2 (NDST-2; 33 and 34).
NDST-2 is an essential enzyme in the biosynthesis of MC
heparin and the lack of this enzyme results in a global re-
duction of stored MC proteases (24, 34). Subsequent char-
acterization of the thrombin-inactivating mechanism in
wild-type cells showed that thrombin was degraded by MC
serine protease activity, predominantly of chymotryptic
type, although it was not possible to firmly establish which
of the potential candidate proteases was the key factor in
the process. Here we investigated the contribution of
Figure 2. Effect of mMCP-4 inactivation on
the storage of CTMC proteases. Extracts were
prepared from peritoneal cells and from ears of
mMCP-4 / , mMCP-4 / , or mMCP-4 / 
littermates. Samples of the extracts were sub-
jected to Western blot analysis using antisera
toward mMCP-4, -5, -6, or CPA as described
in Materials and Methods.
Figure 3. Effect of the
mMCP-4 targeting on MC
morphology and ability to de-
granulate. Peritoneal cells were
recovered from mMCP-4 / 
mice and from  /  or  /  lit-
termates. Cytospin slides were
prepared from unstimulated cells
or after the cells had been sub-
jected to stimulation with either
calcium ionophore A23187
(2  M) or anti-IgE antibody (4
 g/ml) for 30 min. Slides were
stained May-Grünwald/Giemsa.T
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mMCP-4 in the thrombin-inactivating capability of perito-
neal cell populations. The results displayed in Fig. 4 show
that thrombin is rapidly inactivated in mMCP-4 /  cell
cultures after addition of A23187 or anti-IgE antibody to
the cell cultures. In contrast, the inactivation of thrombin
was markedly slower in mMCP-4 /  peritoneal cell cul-
tures after addition of A23187 or anti-IgE, indicating that
mMCP-4 is the key component of the thrombin-inactivat-
ing mechanism present in the peritoneal cell population.
mMCP-4 Inactivation Leads to Reduced Processing of Fi-
bronectin. We have previously shown that NDST-2 / 
peritoneal cells exhibit an impaired ability to process en-
dogenously produced fibronectin, resulting in accumula-
tion of intact fibronectin in the cell culture medium (35).
WT cells, in contrast, continuously degrade the fibronectin
and thus display markedly reduced levels of intact fibronec-
tin in the culture medium. It was shown that the fibronec-
tin, in nonstimulated wild-type cells, was degraded by MC
chymotryptic activity that acted in concert with heparin
proteoglycan (35). However, the exact identity of the fi-
bronectin-degrading protease could not be revealed. To
study the contribution of mMCP-4 in fibronectin turnover
we cultured nonstimulated peritoneal cells from WT and
mMCP-4 null animals and analyzed conditioned media
from the cell cultures for the presence of immunoreactive
fibronectin. From Fig. 5 A it is clear that intact fibronectin
is present in conditioned medium from nonstimulated
mMCP-4 /  cells and that the level of intact fibronectin is
reduced in conditioned medium from mMCP-4 /  perito-
neal cells. Experiments were performed to investigate if
stimulation of the MCs would result in degradation of the
endogenous fibronectin. Indeed, addition of calcium iono-
phore A23187 to the peritoneal cell cultures derived from
mMCP-4 /  mice led to marked fibronectin degradation
whereas very little apparent increase in fibronectin degrada-
tion was observed upon addition of A23187 to mMCP-4 / 
cultures (Fig. 5 A). The results shown in Fig. 5 A were de-
rived from relatively young (8 wk old) mice. When similar
experiments were performed on peritoneal cells from older
(12 wk) mice it was observed that the difference in the
content of intact fibronectin in nonstimulated mMCP-4 / 
versus  /  cultures was much more pronounced (Fig. 5 B).
This is in line with our observation that the level of sur-
face-associated chymase activity increases with increasing
age of the animals (unpublished data). Experiments were
also performed to investigate if mMCP-4 influenced the
levels of cell-associated fibronectin. Cell fractions from
mMCP-4 /  and  /  peritoneal cells were recovered and
analyzed for the presence of fibronectin. Again, intact fi-
bronectin was clearly detected in cell fractions from
Table I. Protease Activities in Peritoneal Cells
Source of cells
Chymotrypsin-like activity
mOD/(min   106 cells)
Trypsin-like activity
mOD/(min   106 cells)
CPA activity
mOD/(min   106 cells)
mMCP-4 /  mice  3.5   2.9 2.0   0.077  14.3   5.0
(n   4) (n   4) (n   4)
mMCP-4 /  mice  n.d. 3.5   2.0  14.7   4.67
(n   4) (n   4) (n   4)
mMCP-4 /  mice 2.2   1.58 1.9   0.51  15.6   3.07
(n   3) (n   4) (n   3)
Extracts were prepared from peritoneal cells and were assayed for trypsin-like, chymotrypsin-like, and CPA activities as described in Materials and
Methods. Note that hydrolysis of the CPA substrate results in decreased absorbance. n.d., none detected.
Table II. Protease Activities in Ear Tissue Extracts
Source of tissue
Chymotrypsin-like activity
mOD/(min   mg tissue)
Trypsin-like activity
mOD/(min   mg tissue)
CPA activity
mOD/(min   mg tissue)
mMCP-4 /  mice 0.52   0.044 2.3   0.31  0.47   0.11
(n   2) (n   2) (n   2)
mMCP-4 /  mice n.d. 2.8   0.87  0.44   0.073
(n   2) (n   2) (n   2)
mMCP-4 /  mice 0.21   0.015 3.7   0.57  0.45   0.064
(n   2) (n   2) (n   2)
Extracts were prepared from ear tissue and were assayed for trypsin-like, chymotrypsin-like, and CPA activities as described in Materials and Methods.
Note that hydrolysis of the CPA substrate results in decreased absorbance. n.d., none detected.T
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mMCP-4 /  cells, but was virtually undetectable in
mMCP-4 /  cells (Fig. 5 C).
Discussion
Earlier studies in which MC granule components have
been deleted have indicated that the granule content of
MCs reflects a dynamic process in which one constituent
may affect the storage of other components. Thus, the in-
activation of the gene for NDST-2, an enzyme that is criti-
cal for the biosynthesis of MC heparin, led to drastically re-
duced levels of histamine and of all neutral proteases in
CTMCs, as well as to a reduction in MC numbers and an
altered MC morphology (24, 34). Further, the inactivation
of the gene for histidine decarboxylase, the enzyme respon-
sible for conversion of histidine to histamine, resulted in
marked effects on gross MC morphology as a well as re-
ductions in stored proteases (31). It has also been reported,
so far only in abstract form, that inactivation of the gene for
mMCP-5 is accompanied by reduced levels of stored CPA
(32). In these cases, where the inactivation of one MC con-
stituent thus leads to a concomitant reduction in other
components, it is clear that conclusions concerning the spe-
cific function of each of the MC granule constituents are
problematic, as any observed effects in a mouse strain lack-
ing one MC granule constituent could be secondary and
due to a difference in the level of other granule compo-
nents. In contrast, we show here that the inactivation of the
gene for mMCP-4 does not lead to any reduction in MC
numbers, apparent changes in MC morphology, or to any
detected effects on other MC granule constituents. Thus,
the mMCP-4 null mouse strain is a relevant model for
studies of the specific function of this chymase.
In earlier reports we demonstrated a reduced ability of
peritoneal cells from NDST-2 null animals to process
thrombin (33) and endogenous fibronectin (35) and char-
acterization of the processing mechanisms in WT cells indi-
cated that MC chymase in complex with heparin pro-
teoglycan was mainly responsible. However, the NDST-2
inactivation leads to a global reduction in all MC granule
components as well as to a marked reduction in MC num-
bers, making it difficult to firmly attribute any effects spe-
cifically to one MC product. Further, since the NDST-2
inactivation is followed by reductions in the storage
(mRNA levels are not affected) of both of the CTMC spe-
cific chymases, mMCP-4 and –5, it was not possible to de-
termine which of the two candidate chymases was mainly
responsible for the fibronectin and thrombin processing.
There was also the possibility that other chymotrypsin-like
enzymes (e.g., cathepsin G) may have contributed. Here
we show that thrombin and fibronectin degradation in the
Figure 4. Targeting of mMCP-4 reduces the ability of peritoneal cells
to inactivate thrombin. Peritoneal cells were prepared from mMCP-4 / 
or  /  littermates and were cultured in serum-free medium. Cells were
incubated overnight and were either cultured further without any treat-
ment or were treated with the calcium ionophore A23187 (2  M) or
with anti-IgE antibody (5  g/ml). After 30 min, thrombin (1  g) was
added. Samples (50  l) from the conditioned media were taken at the
time points indicated and were analyzed for residual thrombin activity
with the chromogenic substrate S-2238. Results are expressed as the
mean of duplicate determinations   range of variation within a single
experiment. The results displayed are representative for 4 individual ex-
periments on different mice.
Figure 5. Effect of the mMCP-4 inactivation on fibronectin processing.
(A) Peritoneal cells were obtained from mMCP-4 /  mice and from
mMCP-4 /  littermates (8 wk old). After overnight culture in serum-free
medium, cells were either cultured further without treatment or treated
with calcium ionophore A23187 (2  M). Conditioned media were col-
lected after a 5 h incubation period. (B) Peritoneal cells were prepared
from mMCP-4 /  or  /  littermates (12 wk old). Conditioned media
were collected at the time points indicated. (C) Cell fractions were ob-
tained from mMCP-4 /  or  /  peritoneal cell cultures, by addition of
SDS-PAGE sample buffer to cell cultures from which the conditioned me-
dia had been removed. (A–C) Conditioned media and cell fractions were
subjected to Western blot analysis using an anti-fibronectin antiserum.T
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peritoneal cell population is drastically reduced in mMCP-
4 /  peritoneal cells, demonstrating that mMCP-4 is the
key factor in the observed processing mechanisms. Interest-
ingly, several previous reports support the notion that fi-
bronectin indeed is an important substrate for MC chy-
mase. In an early study it was demonstrated that human
chymase rapidly degrades fibronectin in a purified system
(36) and more recently it was shown that human chymase
has the ability to release fibronectin degradation products
from connective tissue produced by human airway smooth
muscle cells (37). Moreover, it has been suggested that the
fibronectin degradation products formed by the action of
chymase may be apoptotic (38). These results together with
the present findings indicate that the fibronectin present in
connective tissues may be one of the main physiological
targets for MC chymase. Hence, we may speculate that
MCs have an important role in connective tissue remodel-
ing processes that occur in inflammatory reactions, by pro-
viding proteases that degrade the individual connective tis-
sue components. According to the present data, chymase
could thus act directly on fibronectin. On a different angle,
it has been shown that chymase can promote connective
tissue degradation indirectly by processing the latent form
of matrix metalloproteases 9 (proMMP-9) to its active
counterpart (39). Further, it has been shown that MC
tryptase can contribute to connective tissue destruction in-
directly by activating proMMP-3 (40) and, directly, by de-
grading collagen type VI (41).
The inactivation of mMCP-4 resulted in essentially
complete abolishment of chymotryptic activity recovered
in the peritoneal cell population as well as in ear tissue.
This establishes firmly that mMCP-4 constitutes the main
chymotrypsin-like enzyme at these sites, and rules out
that other chymases or chymotrypsin-like enzymes, e.g.,
mMCP-5 or cathepsin G, significantly contribute to this
type of activity in these tissues. The implication of this
finding is that during MC activation, mMCP-4 represents
by far the dominating chymotrypsin-like activity that is re-
leased into the surrounding tissue. Thus, it is likely that
mMCP-4 will contribute significantly to any physiological
process performed by chymotrypsin-like proteases in tissues
that contain CTMCs.
The exact biological function(s) of the MC chymases is
an intriguing issue. As noted in the Introduction, many
lines if evidence suggest a harmful role of chymase in vari-
ous inflammatory conditions. However, it is likely that
MC chymases also carry beneficial functions. Indeed, it has
been shown that inactivation of the MMC-specific chy-
mase, mMCP-1, results in an impaired ability to combat
infection by the nematode Trichinella spiralis (42). Further,
MCs have been shown to be involved in defense against
bacterial infection (43, 44), although the specific contribu-
tion of MC proteases have not been addressed so far. We
believe that the mMCP-4 null mouse strain will provide a
model in which the specific function of this chymase in a
number of pathological conditions may be addressed. Fur-
ther, as mMCP-4 may be the functional counterpart of the
human chymase, we believe that the findings presented
here are relevant in the context of the biological function
of human chymase.
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